消化性潰瘍治療薬市場-世界の産業規模、動向、機会、予測、製品タイプ別、適応疾患別、流通チャネル別、地域別、競合別、2019～2029年

消化性潰瘍治療薬の世界市場は、2023年に34億2,000万米ドルと評価され、予測期間では2029年までCAGR 3.25％で安定した成長が予測されています。

消化性潰瘍は、世界中で数100万人が罹患している一般的な胃腸疾患です。胃、小腸、食道にできる痛みを伴うただれは、主に消化管の保護膜が侵食されることによって引き起こされます。消化性潰瘍治療薬の世界市場は、医療の進歩や消化性潰瘍の病態に対する理解の高まりにより、年々大きく発展しています。

消化性潰瘍の有病率の増加により、消化性潰瘍治療薬の世界市場は大幅な成長を遂げています。ストレス、喫煙、過度のアルコール摂取、非ステロイド性抗炎症薬（NSAIDs）の広範な使用などの生活習慣が、症例の増加に寄与しています。その結果、症状を緩和し治癒を促進する効果的な薬剤が常に求められています。製薬業界は、消化性潰瘍治療薬としてより効果的で安全な薬剤の開発において大きな進歩を遂げています。胃酸の分泌を抑えるプロトンポンプ阻害薬（PPI）や、胃細胞に対するヒスタミンの作用を阻害するH2受容体拮抗薬は、消化性潰瘍の管理に革命をもたらしました。消化性潰瘍に関連する危険因子や症状に対する認識が高まり、早期診断と治療薬を求める人が増えています。このため、消化性潰瘍治療薬の需要が急増しています。消化性潰瘍の主要原因としてヘリコバクター・ピロリ菌が発見されたことで、この細菌を効果的に除菌できる標的抗生物質療法が登場しました。このアプローチにより、長期的な酸抑制薬の必要性が減少しています。

主要市場の促進要因

消化性潰瘍の有病率の上昇が消化性潰瘍治療薬の世界市場を牽引

高齢者人口の増加が消化性潰瘍治療薬の世界市場を牽引

主要市場課題

ジェネリック医薬品の競合激化

ジェネリック医薬品の有効性と安全性

抗生物質耐性

治療薬パラダイムの変化

規制上の課題

主要市場動向

技術の進歩

セグメント別洞察

製品タイプ別洞察

流通チャネル別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 消化性潰瘍治療薬の世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別（プロトンポンプ阻害薬、カリウム競合酸遮断薬（P-CAB）、制酸薬、H2-拮抗薬、抗生物質、潰瘍保護薬）
  • 適応疾患別（胃炎、胃潰瘍、十二指腸潰瘍、胃食道逆流症（GERD））
  • 流通チャネル別（病院薬局、小売薬局、eコマース）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 製品タイプ別
  • 適応疾患別
  • 販売チャネル別
  • 地域別

第5章 アジア太平洋の消化性潰瘍治療薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の消化性潰瘍治療薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の消化性潰瘍治療薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の消化性潰瘍治療薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの消化性潰瘍治療薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と新興国市場開拓

• 製品発表
• 合併・買収

第12章 消化性潰瘍治療薬の世界市場のSWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Daewoong Pharmaceutical Co., Ltd
• Takeda Pharmaceutical Co., Ltd.
• Pfizer Inc.
• AstraZeneca plc.
• RedHill Biopharma Ltd.
• Zydus Lifesciences Limited
• ANI Pharmaceuticals, Inc.（Novitium Pharma LLC.）
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• Yuhan Corporation

第15章 戦略的提言

第16章 戦略的提言当社について免責事項

Global Peptic Ulcer Drugs Market was valued at USD 3.42 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 3.25% through 2029. Peptic ulcers are a common gastrointestinal ailment that affects millions of people worldwide. These painful sores, which can develop in the stomach, small intestine, or esophagus, are primarily caused by the erosion of the protective lining of the digestive tract. The global peptic ulcer drugs market has evolved significantly over the years, driven by advancements in medical science and a growing understanding of the condition.

The global peptic ulcer drugs market has witnessed substantial growth due to the increasing prevalence of peptic ulcers. Lifestyle factors such as stress, smoking, excessive alcohol consumption, and the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) have contributed to the rise in cases. As a result, there is a constant demand for effective medications to alleviate symptoms and promote healing. The pharmaceutical industry has made significant strides in developing more effective and safer medications for peptic ulcer treatment. Proton pump inhibitors (PPIs), which reduce stomach acid production, and H2 receptor antagonists, which block the action of histamine on stomach cells, have revolutionized peptic ulcer management. With increased awareness of the risk factors and symptoms associated with peptic ulcers, more individuals are seeking early diagnosis and treatment. This has led to an upsurge in demand for peptic ulcer drugs. The discovery of Helicobacter pylori as a major cause of peptic ulcers has led to targeted antibiotic therapies that can effectively eradicate the bacterium. This approach has reduced the need for long-term acid-suppressing medications.

Key Market Drivers

Rising Prevalence of Peptic Ulcers is Driving the Global Peptic Ulcer Drugs Market

Peptic ulcers have long been a significant health concern worldwide, affecting millions of individuals across various age groups and geographic regions. These painful and often debilitating conditions have a profound impact on patients' quality of life, healthcare systems, and the pharmaceutical industry. In recent years, the global peptic ulcer drugs market has experienced substantial growth due to the rising prevalence of peptic ulcers.Peptic ulcers are open sores that develop in the lining of the stomach, small intestine, or oesophagus. They are primarily caused by the erosion of the protective mucus layer in the stomach and duodenum, leading to the exposure of sensitive tissues to stomach acid and digestive enzymes. Common symptoms of peptic ulcers include abdominal pain, burning sensations, bloating, and indigestion. In severe cases, ulcers can lead to complications such as bleeding, perforation, or obstruction.

The bacterium Helicobacter pylori is a leading cause of peptic ulcers. It's estimated that up to 80% of peptic ulcers are linked to H. pylori infection. This bacterium is highly prevalent, especially in developing countries, where poor sanitation and hygiene contribute to its spread.Modern lifestyles are often associated with high levels of stress, which can trigger or exacerbate peptic ulcers. Stress disrupts the natural balance of stomach acid and protective mucus production, making the stomach more susceptible to damage.Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and aspirin, are commonly used for pain relief. However, long-term or excessive use of these medications can lead to peptic ulcers, as they can erode the stomach lining.As the global population ages, the prevalence of peptic ulcers is expected to increase. Older individuals are more likely to develop ulcers due to factors like decreased mucus production and slower tissue repair.

The rising prevalence of peptic ulcers is a concerning global health issue that is contributing to the growth of the peptic ulcer drugs market. Factors such as H. pylori infections, the widespread use of NSAIDs, increasing stress levels, and an aging population are driving the increase in peptic ulcer cases. However, the pharmaceutical industry's commitment to research and development, coupled with improvements in diagnosis and treatment, are helping patients manage their conditions more effectively. As the healthcare sector continues to address the challenges posed by peptic ulcers, the global market for peptic ulcer drugs is expected to grow, benefiting patients and stakeholders alike.

Expanding Geriatric Population is Driving the Global Peptic Ulcer Drugs Market

The global healthcare landscape is experiencing a significant shift as the world's population continues to age. With the gradual rise in life expectancy, the geriatric population is expanding, creating new challenges and opportunities for various industries, including pharmaceuticals. One noteworthy consequence of this demographic change is the increased prevalence of age-related health conditions, such as peptic ulcers. As a result, the global peptic ulcer drugs market is witnessing substantial growth, driven by the healthcare needs of the elderly population The global population is aging rapidly. In many developed countries, people aged 65 and older make up a substantial portion of the population, and this trend is expected to continue. As people age, their bodies undergo numerous physiological changes, making them more prone to various medical conditions, including peptic ulcers.

With age, the stomach's ability to produce the mucous layer that shields it from stomach acid declines, making the stomach lining more susceptible to ulcer formation. Elderly individuals are more likely to use NSAIDs, which can increase the risk of peptic ulcers. Chronic pain and conditions like osteoarthritis often require regular use of these drugs. The prevalence of H. pylori infection increases with age. This bacterium is a leading cause of peptic ulcers and can lead to complications in older individuals. The elderly often have multiple health conditions, which can complicate the management of peptic ulcers and necessitate the use of additional medications.

As the elderly population grows, so does the demand for medications to treat peptic ulcers and related conditions. This increased demand is a primary driver of market growth. Pharmaceutical companies are investing in research and development to create more effective and tolerable peptic ulcer drugs. These new medications aim to address the unique needs and challenges faced by older patients. With the presence of comorbidities in older adults, there is a trend toward developing combination therapies that can simultaneously manage peptic ulcers and other conditions, streamlining treatment regimens for the elderly. Tailoring peptic ulcer treatments to individual patients' needs becomes increasingly important in the context of the elderly population. Genetic and personalized medicine approaches are being explored to optimize treatment outcomes.

Key Market Challenges

Increasing Generic Competition

One of the primary challenges in the global peptic ulcer drugs market is the increasing competition from generic drug manufacturers. As many peptic ulcer drugs have been on the market for decades, their patents have expired, allowing generic versions to enter the market. These generics are often more affordable, which can lead to a reduction in market share for brand-name drugs. This competition can affect the revenue and profitability of pharmaceutical companies that produce these drugs.

Generic Drug Efficacy and Safety

While generic drugs offer cost-effective alternatives, their efficacy and safety can sometimes be a concern. Patients and healthcare providers may worry about the consistency and quality of generic drugs, which can hinder their adoption. Ensuring the effectiveness and safety of generic peptic ulcer drugs is a challenge that both manufacturers and regulatory bodies must address.

Antibiotic Resistance

A significant portion of peptic ulcers is caused by Helicobacter pylori infection, which is typically treated with a combination of antibiotics. However, the growing problem of antibiotic resistance poses a challenge in the effective treatment of peptic ulcers. As bacteria become more resistant to commonly used antibiotics, healthcare providers must explore alternative treatment options, which may not be as readily available or effective.

Changing Treatment Paradigms

The treatment of peptic ulcers has evolved over the years. In addition to antibiotics and acid-reducing drugs, other therapies like proton pump inhibitors (PPIs) have become popular for managing symptoms. While PPIs are effective in providing relief, there are concerns about their long-term use and potential side effects, including an increased risk of bone fractures and kidney problems. Pharmaceutical companies face the challenge of balancing the benefits of these drugs with their potential risks, while also meeting the evolving needs of patients.

Regulatory Challenges

Pharmaceutical companies must navigate complex regulatory environments when developing and marketing peptic ulcer drugs. Regulatory agencies often demand extensive clinical trials to prove the safety and efficacy of these medications. Meeting these requirements can be costly and time-consuming, leading to delays in bringing new treatments to market.

Key Market Trends

Technological Advancements

The global healthcare landscape is experiencing a transformation, largely driven by technological advancements. One area where these advancements are making a significant impact is in the treatment of peptic ulcers. Peptic ulcers are painful sores that develop on the lining of the stomach, small intestine, or esophagus, and they affect millions of people worldwide. With the development of cutting-edge technologies and innovative pharmaceuticals, the global peptic ulcer drugs market is thriving.

One of the most significant technological advancements in the diagnosis of peptic ulcers is the use of advanced endoscopy and imaging techniques. Endoscopic examinations can provide high-resolution images of the digestive tract, enabling healthcare professionals to detect and diagnose ulcers more accurately and at an earlier stage.In addition to traditional endoscopy, non-invasive diagnostic tests have emerged. These include breath tests and blood tests that can detect the presence of Helicobacter pylori, a common cause of peptic ulcers, without the need for invasive procedures.AI and machine learning algorithms are being employed to analyze medical imaging data, helping healthcare professionals identify ulcers and other abnormalities more quickly and accurately.

The development of more targeted medications has significantly improved the treatment of peptic ulcers. Proton pump inhibitors (PPIs) and H2 receptor antagonists are examples of drugs that help reduce stomach acid production, allowing ulcers to heal.Advances in antibiotic therapy have made it possible to eradicate Helicobacter pylori, the bacterium responsible for many peptic ulcers. This targeted approach has led to more effective treatment and a lower risk of recurrence.Technological advancements have also led to the development of innovative drug delivery systems, such as sustained-release formulations, which enhance the efficacy and convenience of treatment for peptic ulcers.Telemedicine and telehealth technologies are improving patient access to healthcare professionals, allowing for timely consultations and monitoring during ulcer treatment, especially in remote or underserved areas.

Segmental Insights

Product Type Insights

Based on the category of Product Type, Proton Pump Inhibitors emerged as the dominant segment in the global market for Peptic Ulcer Drugs in 2023. Proton Pump Inhibitors are a class of drugs that reduce the production of stomach acid by blocking the proton pump, which is responsible for the secretion of gastric acid in the stomach lining. Proton Pump Inhibitors have shown exceptional efficacy in reducing stomach acid, making them highly effective in treating peptic ulcers and related conditions. They help in the healing of ulcers and provide relief from the symptoms, including heartburn and indigestion. Proton Pump Inhibitors are generally well-tolerated and have fewer side effects compared to other classes of drugs used in peptic ulcer treatment. This has contributed to their widespread acceptance among patients. Proton Pump Inhibitors are available in various formulations, including oral capsules, tablets, and even intravenous options for more severe cases. This versatility in administration makes them suitable for a wide range of patients. In many countries, Proton Pump Inhibitors are available over the counter, making them easily accessible to patients without a prescription. This convenience further boosts their dominance in the market. Proton Pump Inhibitors are cost-effective both for patients and healthcare systems, making them an attractive option for long-term ulcer management and prevention.

Distribution Channel Insights

The Hospital Pharmacies segment is projected to experience rapid growth during the forecast period. One of the primary reasons hospital pharmacies dominate the peptic ulcer drugs market is the significant number of patients admitted to hospitals with severe peptic ulcer complications. These patients often require intravenous administration of drugs, and hospitals are better equipped to provide this level of care. Hospital pharmacies are instrumental in the treatment of peptic ulcer complications, such as gastrointestinal bleeding, perforation, or obstruction. In these cases, patients require immediate and specialized care, often involving complex drug regimens. Hospitals have a systematic approach to medication management. They can ensure that patients receive the right dosage at the right time, increasing treatment effectiveness and reducing the risk of non-adherence. Hospital pharmacies have a close working relationship with healthcare professionals, including gastroenterologists and surgeons. This collaboration results in a more comprehensive and individualized approach to treatment.

Regional Insights

North America emerged as the dominant region in the global Peptic Ulcer Drugs market in 2023. One of the key factors contributing to North America's prominence in the global peptic ulcer drugs market is the high prevalence of peptic ulcers in the region. The United States, in particular, has a significant number of reported cases. Lifestyle factors such as stress, unhealthy eating habits, and the overuse of nonsteroidal anti-inflammatory drugs (NSAIDs) have contributed to the rise in peptic ulcer cases in North America. This high incidence of peptic ulcers has naturally led to a strong demand for peptic ulcer drugs. North America boasts a robust healthcare infrastructure with access to modern medical facilities, a highly trained workforce, and a strong pharmaceutical industry. These factors have created an environment conducive to research and development of cutting-edge drugs for peptic ulcers. Additionally, patients in North America have access to timely diagnosis and treatment, making it easier for pharmaceutical companies to introduce new drugs and treatments in the market.

Key Market Players

Daewoong Pharmaceutical Co., Ltd

Takeda Pharmaceutical Co., Ltd.

Pfizer Inc.

AstraZeneca plc.

RedHill Biopharma Ltd.

Zydus Lifesciences Limited

ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)

Boehringer Ingelheim International GmbH

Eisai Co. Ltd.

Yuhan Corporation

Report Scope:

In this report, the Global Peptic Ulcer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptic Ulcer Drugs Market,By Product Type:

• Proton Pump Inhibitors
• Potassium-Competitive Acid Blocker (P-CAB)
• Antacids
• H2- Antagonist
• Antibiotics
• Ulcer Protective

Peptic Ulcer Drugs Market,By Disease Indication:

• Gastitis
• Gastric Ulcer
• Duodenal Ulcer
• Gastroesophageal Reflux Disease (GERD)

Peptic Ulcer Drugs Market,By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Peptic Ulcer Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Peptic Ulcer Drugs Market.

Available Customizations:

Global Peptic Ulcer Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Peptic Ulcer Drugs Market Outlook

• 4.1.Market Size Forecast
  • 4.1.1.By Value
• 4.2.Market Share Forecast
  • 4.2.1.By Product Type (Proton Pump Inhibitors,Potassium-Competitive Acid Blocker (P-CAB), Antacids,H2- Antagonist,Antibiotics,Ulcer Protective)
  • 4.2.2.By Disease Indication (Gastitis,Gastric Ulcer,Duodenal Ulcer,Gastroesophageal Reflux Disease (GERD))
  • 4.2.3.By Distribution Channel (Hospital Pharmacies,Retail Pharmacies, E-Commerce)
  • 4.2.4.By Region
  • 4.2.5.By Company (2023)
• 4.3.Market Map
  • 4.3.1.By Product Type
  • 4.3.2.By Disease Indication
  • 4.3.3.By Distribution Channel
  • 4.3.4.By Region

5.Asia Pacific Peptic Ulcer Drugs Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Product Type
  • 5.2.2.By Disease Indication
  • 5.2.3.By Distribution Channel
  • 5.2.4.By Country
• 5.3.Asia Pacific: Country Analysis
  • 5.3.1.China Peptic Ulcer Drugs Market Outlook
    • 5.3.1.1.Market Size Forecast
      • 5.3.1.1.1.By Value
    • 5.3.1.2.Market Share Forecast
      • 5.3.1.2.1.By Product Type
      • 5.3.1.2.2.By Disease Indication
      • 5.3.1.2.3.By Distribution Channel
  • 5.3.2.India Peptic Ulcer Drugs Market Outlook
    • 5.3.2.1.Market Size Forecast
      • 5.3.2.1.1.By Value
    • 5.3.2.2.Market Share Forecast
      • 5.3.2.2.1.By Product Type
      • 5.3.2.2.2.By Disease Indication
      • 5.3.2.2.3.By Distribution Channel
  • 5.3.3.Australia Peptic Ulcer Drugs Market Outlook
    • 5.3.3.1.Market Size Forecast
      • 5.3.3.1.1.By Value
    • 5.3.3.2.Market Share Forecast
      • 5.3.3.2.1.By Product Type
      • 5.3.3.2.2.By Disease Indication
      • 5.3.3.2.3.By Distribution Channel
  • 5.3.4.Japan Peptic Ulcer Drugs Market Outlook
    • 5.3.4.1.Market Size Forecast
      • 5.3.4.1.1.By Value
    • 5.3.4.2.Market Share Forecast
      • 5.3.4.2.1.By Product Type
      • 5.3.4.2.2.By Disease Indication
      • 5.3.4.2.3.By Distribution Channel
  • 5.3.5.South Korea Peptic Ulcer Drugs Market Outlook
    • 5.3.5.1.Market Size Forecast
      • 5.3.5.1.1.By Value
    • 5.3.5.2.Market Share Forecast
      • 5.3.5.2.1.By Product Type
      • 5.3.5.2.2.By Disease Indication
      • 5.3.5.2.3.By Distribution Channel

6.Europe Peptic Ulcer Drugs Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Product Type
  • 6.2.2.By Disease Indication
  • 6.2.3.By Distribution Channel
  • 6.2.4.By Country
• 6.3.Europe: Country Analysis
  • 6.3.1.France Peptic Ulcer Drugs Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Product Type
      • 6.3.1.2.2.By Disease Indication
      • 6.3.1.2.3.By Distribution Channel
  • 6.3.2.Germany Peptic Ulcer Drugs Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Product Type
      • 6.3.2.2.2.By Disease Indication
      • 6.3.2.2.3.By Distribution Channel
  • 6.3.3.Spain Peptic Ulcer Drugs Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Product Type
      • 6.3.3.2.2.By Disease Indication
      • 6.3.3.2.3.By Distribution Channel
  • 6.3.4.Italy Peptic Ulcer Drugs Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Product Type
      • 6.3.4.2.2.By Disease Indication
      • 6.3.4.2.3.By Distribution Channel
  • 6.3.5.United Kingdom Peptic Ulcer Drugs Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Product Type
      • 6.3.5.2.2.By Disease Indication
      • 6.3.5.2.3.By Distribution Channel

7.North America Peptic Ulcer Drugs Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Product Type
  • 7.2.2.By Disease Indication
  • 7.2.3.By Distribution Channel
  • 7.2.4.By Country
• 7.3.North America: Country Analysis
  • 7.3.1.United States Peptic Ulcer Drugs Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Product Type
      • 7.3.1.2.2.By Disease Indication
      • 7.3.1.2.3.By Distribution Channel
  • 7.3.2.Mexico Peptic Ulcer Drugs Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Product Type
      • 7.3.2.2.2.By Disease Indication
      • 7.3.2.2.3.By Distribution Channel
  • 7.3.3.Canada Peptic Ulcer Drugs Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Product Type
      • 7.3.3.2.2.By Disease Indication
      • 7.3.3.2.3.By Distribution Channel

8.South America Peptic Ulcer Drugs Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Product Type
  • 8.2.2.By Disease Indication
  • 8.2.3.By Distribution Channel
  • 8.2.4.By Country
• 8.3.South America: Country Analysis
  • 8.3.1.Brazil Peptic Ulcer Drugs Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Product Type
      • 8.3.1.2.2.By Disease Indication
      • 8.3.1.2.3.By Distribution Channel
  • 8.3.2.Argentina Peptic Ulcer Drugs Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Product Type
      • 8.3.2.2.2.By Disease Indication
      • 8.3.2.2.3.By Distribution Channel
  • 8.3.3.Colombia Peptic Ulcer Drugs Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Product Type
      • 8.3.3.2.2.By Disease Indication
      • 8.3.3.2.3.By Distribution Channel

9.Middle East and Africa Peptic Ulcer Drugs Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Product Type
  • 9.2.2.By Disease Indication
  • 9.2.3.By Distribution Channel
  • 9.2.4.By Country
• 9.3.MEA: Country Analysis
  • 9.3.1.South Africa Peptic Ulcer Drugs Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Product Type
      • 9.3.1.2.2.By Disease Indication
      • 9.3.1.2.3.By Distribution Channel
  • 9.3.2.Saudi Arabia Peptic Ulcer Drugs Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Product Type
      • 9.3.2.2.2.By Disease Indication
      • 9.3.2.2.3.By Distribution Channel
  • 9.3.3.UAE Peptic Ulcer Drugs Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Product Type
      • 9.3.3.2.2.By Disease Indication
      • 9.3.3.2.3.By Distribution Channel

10.Market Dynamics

• 10.1.Drivers
• 10.2.Challenges

11.Market Trends Developments

• 11.1.Recent Developments
• 11.2.Product Launches
• 11.3.Mergers Acquisitions

12.Global Peptic Ulcer Drugs Market: SWOT Analysis

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Product

14.Competitive Landscape

• 14.1.Daewoong Pharmaceutical Co., Ltd
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Product Services
  • 14.1.5.Financials (In case of listed)
  • 14.1.6.Recent Developments
  • 14.1.7.SWOT Analysis
• 14.2.Takeda Pharmaceutical Co., Ltd.
• 14.3.Pfizer Inc.
• 14.4.AstraZeneca plc.
• 14.5.RedHill Biopharma Ltd.
• 14.6.Zydus Lifesciences Limited
• 14.7.ANI Pharmaceuticals, Inc.(Novitium Pharma LLC.)
• 14.8.Boehringer Ingelheim International GmbH
• 14.9.Eisai Co. Ltd.
• 14.10.Yuhan Corporation

15.Strategic Recommendations

16.About Us Disclaimer